You are here: Industry Insights > Portola

News List

NICE backs Portola's Ondexxya pharmatimes
September 14, 2020
The National Institute for Health and Care Excellence (NICE) has published the outcome of an appraisal consultation document backing NHS funds for restricted use of Portola's Ondexxya (andexanet alfa) as an option for reversing anticoagulation ...
Alexion to buy biopharmaceutical firm Portola in $1.41bn deal pharmaceutical-business-review
May 06, 2020
Alexion Pharmaceuticals has signed an agreement to acquire commercial-stage biopharmaceutical company Portola in a deal valued at around $1.41bn.
Portola Pharmaceuticals R&D Exec to Retire contractpharma
April 26, 2019
Portola Pharmaceuticals, Inc.: Dr. John Curnutte, M.D., Ph.D., executive vice president and head of R&D, will retire on May 17, 2019, after more than eight years of service.
Portola's Andexxa bleeding antidote wins FDA nod but will see limited release fiercepharma
May 08, 2018
Portola has finally overcome FDA concerns to win approval of its coagulation factor Xa, a bleeding antidote for some of the new generation blood thinners like Xarelto and Eliquis. Portola will launch Andexxa next month, although initial supplies will be l
Surprise! FDA Clears Launch For Portola's Potential Multibillion-Dollar Drug Next Month biospace
December 22, 2017
FDA continues to hand out some early Christmas presents to pharma companies. This week, Portola Pharmaceuticals said the agency approved its Prior Approval Supplement (PAS) for Bevyxxa (betrixaban) ahead of its scheduled Jan. 30, 2018 action date.
US approval for Portola’s BevyxXa pharmatimes
June 28, 2017
Portola Pharmaceuticals’ BevyxXa has been cleared by the US Food and Drug Administration for preventing blood clots in hospitalised patients.